explore -WSS

explore

author：Wikipedia 2025-10-01 21:40:59 - browse：478

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Court strikes down limits on filming of police in Arizona

WSS

Will the FTC rein in IQVIA's health data empire?

The haunting brain science of long Covid

What it's like to live with paralysis for one psychologist

'Investigate these claims': UFO transparency at center of House hearing

Rise in cancer among younger people worries and puzzles doctors

As Taiwan prepares for anti

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Continuity nursing helped my family in our darkest PICU moments

What to know about Saharan dust affecting the US and how it can affect health

Malaria cases in Florida and Texas: Here’s what you need to know

Artificial intelligence advances fuel industry trying to preserve loved ones after death

As demand for Covid shots wanes, Moderna seeks its next success

New rules on organ donation and transplantation 'will bring chaos'

Cancer drug shortages should be causing more outrage

New lawsuit accuses health insurer Cigna of denying claims in bulk

Malaria cases in Florida and Texas: Here’s what you need to know

Democrats decry new health bill for going easy on private equity

hotspot

Device maker Teleflex to acquire urology company for $600M

Court strikes down limits on filming of police in Arizona

New lawsuit accuses health insurer Cigna of denying claims in bulk

Elizabeth Warren probes abortion access

Review: 'Barbie' will hit you like a shot in the heart

In new study, freeze

leisure time

focus

explore

entertainment